Chair(s)
TBC
Introduction:
This plenary will explore the growing global focus on longevity, from emerging biological-age diagnostics to novel therapies, and the implications for health systems and clinical practice. It will highlight advances in areas such as precision medicine, ageing biology, and long-term management of chronic conditions across the life course.
The session will also emphasise the role of pharmacists in ensuring the safe, evidence-based and equitable application of these innovations, including medicines optimisation, patient-centred care, and addressing regulatory and access challenges in the evolving longevity landscape.
This plenary will also highlight collaboration with the FIP Special Interest Groups, underlining the importance of connecting practice, education and science in the global longevity agenda.
Programme:
| 09:00 – 09:10 | Opening remarks by the co-chairs |
| 09:10 – 09:30 | From lifespan to healthspan: The science of longevity and its implications for pharmacy |
| Prof. Andrea B. Maier, MD, PhD, Centre for Healthy Longevity, National University of Singapore; Founding President, Healthy Longevity Medicine Society | |
| 09:30 – 09:50 | Longevity, life course and health systems: Advancing healthy ageing through integrated care |
| Prof. Cláudia Cavadas, PharmD, PhD, Head of the Neuroendocrinology and Aging Group, Coimbra, Portugal | |
| 09:50 – 10:10 | How healthcare professionals can help extend healthspan through prevention, early detection, and personalized medicine |
| Speaker to be confirmed | |
| 10:10 – 10:25 | Panel discussion and Q&A |
| 10:25 – 10:30 | Closing remarks by the co-chairs |
Learning objectives:
1. Describe key scientific and clinical developments shaping the global longevity agenda, including ageing biology, precision medicine and emerging therapies.
2. Discuss the implications of longevity science for pharmacy, pharmaceutical sciences, health systems and long-term chronic disease management.
3. Identify opportunities for pharmacists to support safe, evidence-based and patient-centred longevity care.
4. Recognise regulatory, access and equity considerations related to emerging diagnostics, therapies and innovations in the longevity field.
Take home messages:
As longevity science advances, pharmacists have a critical role in ensuring that emerging diagnostics, therapies and personalised approaches are applied safely, equitably and in ways that support healthy ageing.
FIP Development Goals:
To learn more about these FIP Development Goals, click on the links below.
FIP Development Goal 14: Medicines Expertise
FIP Development Goal 15: People-Centred Care
FIP Development Goal 18: Access to Medicines, Devices & Services
